【MGRC 0155 交流专区】基因组学资源

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2015	31 Dec 2014	31 Dec 2015	31 Dec 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,194	3,693	6,793	6,250
2	Profit/(loss) before tax	490	1,355	1,396	1,853
3	Profit/(loss) for the period	489	1,353	1,395	1,850
4	Profit/(loss) attributable to ordinary equity holders of the parent	489	1,353	1,395	1,850
5	Basic earnings/(loss) per share (Subunit)	0.52	1.44	1.48	1.97
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2024		0.1876

icy97

Type	Announcement
Subject	OTHERS
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD- DEBTORS' ARRANGEMENT
The Board of Directors of the Company wishes to announce that it has received a letter dated 28 March 2016 from Lembaga Kemajuan Tanah Persekutuan ("FELDA") stating that the Company's debtor, Felda Wellness Corporation Sdn Bhd ("FWC") has been wound up and that FELDA intends to settle in full, all debts which may be due and owing by FWC to the Company within twenty one (21) working days of the date of the Company's acceptance of the settlement proposal. The announcement is dated 29 March 2016.

icy97

Type	Announcement
Subject	OTHERS
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD- DEBTORS' ARRANGEMENT
(All abbreviations used in this announcement are defined in the announcement dated 29 March 2016). Further to the announcement made on 29 March 2016, the Board of Directors of the Company wishes to announce that in fulfillment of the terms of the settlement proposal dated 28 March 2016 from FELDA, FELDA has settled in full all debts due and owing by FWC to the Company within the timeframe stipulated in the settlement proposal.   This announcement is dated 29 April 2016.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2016	31 Mar 2015	31 Mar 2016	31 Mar 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,788	4,293	8,581	10,543
2	Profit/(loss) before tax	229	1,298	1,625	3,151
3	Profit/(loss) for the period	228	1,296	1,623	3,146
4	Profit/(loss) attributable to ordinary equity holders of the parent	228	1,296	1,623	3,146
5	Basic earnings/(loss) per share (Subunit)	0.24	1.38	1.72	3.34
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2048		0.1876

icy97

Type	Announcement
Subject	OTHERS
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC")- PROJECT ARRANGEMENT
(All abbreviations used in this announcement are defined in the announcement dated 4 November 2014). Further to the announcements made on 4 November 2014, 29 March 2016 and 29 April 2016, the Board of Directors wishes to announce that the Board of FELDA has agreed for MGRC to continue the project with FWC to completion. This announcement is dated 4 July 2016.

icy97

业绩欠佳‧大马基因有何动静？

读者郑少强问：

大马基因资源（MGRC，0155，创业板科技组）在2010年首次公开售股（IPO）上市时，我有申请到这个股，现在还持有此股项。最近它好像没有什么消息，业务表现及财务如何，过去业绩不是很好？现在是卖出的时候吗？

答：大马基因资源主要从事基因分析及扫描领域，其最新业绩，截至2016年3月31日为止第三季，该公司净利减少至22万8000令吉（每股净利为0.24仙），前期净利则为129万6000令吉（每股净利为1.38仙）。营业额为178万8000令吉，前期为429万3000令吉。

首9个月的净利为162万3000令吉（每股净利1.72仙），前期净利为314万6000令吉（每股净利为3.34仙）。首9个月的营业额为858万1000令吉，前期为1054万3000令吉。该公司的每股资产值为20.48仙。

在宣布上述业绩时，该公司谈到业务展望时指出，虽然宏观经济展望具挑战，惟该公司的基因扫描服务日益获得客户的接受，特别是客户开始意识到对公司服务的需要，所以，该公司将努力开拓及渗透尚未开发的市场。

资产负债表精简

财务情况方面，该公司的资产负债表相当精简；截至2016年3月31日为止，该公司的总资产为2471万3000令吉，主要包括非流动资产下的联营投资为998万8000令吉、无形资产为193万5000令吉。流动资产的贸易及其他应收款项为1040万3000令吉、库存为132万4000令吉。

该公司的总负债为543万8000令吉，即是流动负债下的贸易及其他应付款项为543万8000令吉。

该公司股本为941万令吉，由9410万股每股面值10仙的股票组成。若以该公司每股市价50仙为准，它的总市值即达到4705万令吉。

资料记录显示，该公司是于2010年杪上市，在2011年财政年（截至6月30日）全年净利为263万6000令吉，接着在未来3年皆蒙受亏损，即2012年净亏366万令吉、2013年净亏900万3000令吉、2014年净亏为430万2000令吉，直至2015年再获净利362万3000令吉。

该公司在2015年取得盈利，其中主因是取得联邦土地发展局（Felda）旗下公司-Felda Wellness公司颁予一项总值1900万令吉研发合约推动，目前后者已经结业。

近年来并没有证券行进剖析及推荐。

文章来源：
星洲日报‧投资致富‧投资问诊‧文：李文龙‧2016.07.31

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2016	30 Jun 2015	30 Jun 2016	30 Jun 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,851	3,355	10,432	13,898
2	Profit/(loss) before tax	119	478	1,744	3,629
3	Profit/(loss) for the period	114	477	1,737	3,623
4	Profit/(loss) attributable to ordinary equity holders of the parent	114	477	1,737	3,623
5	Basic earnings/(loss) per share (Subunit)	0.12	0.51	1.85	3.85
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2060		0.1876

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT
On behalf of the Board of Directors of MGRC, TA Securities Holdings Berhad wishes to announce that the Company proposes to undertake the proposed private placement of new ordinary shares of RM0.10 each in MGRC, representing not more than ten percent (10%) of the issued and paid-up share capital of MGRC (“Proposed Private Placement”). Please refer to the attachment for further details of the announcement. This announcement is dated 17 October 2016.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5233057

Attachments MGRC - Announcement (Final).pdf

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR THE "COMPANY")PRIVATE PLACEMENT OF NEW ORDINARY SHARES OF RM0.10 EACH IN MGRC, REPRESENTING NOT MORE THAN TEN PERCENT (10%) OF THE ENLARGED ISSUED AND PAID-UP SHARE CAPITAL OF MGRC ("PRIVATE PLACEMENT")
We refer to the announcements dated 17 October 2016, 20 October 2016 and 27 October 2016 in relation to the Private Placement (“Announcements”). Unless otherwise defined, the definitions set out in the Announcements shall apply herein. On behalf of MGRC, TA Securities wishes to announce that the Board has on 27 October 2016 fixed the issue price for 9,410,000 Placement Shares at RM0.48 each (“Issue Price”). The Issue Price represents a premium of RM0.0340 or approximately 7.62% over the five (5)-day volume weighted average market price of MGRC Shares from 20 October 2016 up to and including 26 October 2016 of RM0.4460. This announcement is dated 27 October 2016.

icy97

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	Private placement of new ordinary shares of RM0.10 each in MGRC ("MGRC Shares") representing not more than ten percent (10%) of the issued and paid-up share capital of MGRC ("Private Placement")
No. of shares issued under this corporate proposal	9,410,000
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.4800
Par Value ($$)	Malaysian Ringgit (MYR)   0.100
Latest issued and paid up share capital after the above corporate proposal in the following
Units	103,510,480
Currency	Malaysian Ringgit (MYR) 10,351,048.000
Listing Date	08 Nov 2016

icy97

Notice of Interest Sub. S-hldr (29A)

MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD

Particulars of Substantial Securities Holder

Name	TAN SRI DATO' SERI KOH KIN LIP, JP
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary share of RM0.10 each
Name & address of registered holder	CIMSEC Nominees (Tempatan) Sdn. Bhd. CIMB Bank for Koh Kin Lip17th Floor, Menara CIMB,Jalan Stesen Sentral 2,Kuala Lumpur Sentral,50470 Kulua Lumpur

Date interest acquired & no of securities acquired
Currency	Malaysian Ringgit (MYR)
Date interest acquired	04 Nov 2016
No of securities	5,200,000
Circumstances by reason of which Securities Holder has interest	Acquisition of shares via Private Placement
Nature of interest	Direct
Price Transacted ($$)
Total no of securities after change
Direct (units)	5,200,000
Direct (%)	5.024
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Date of notice	10 Nov 2016

哭哭鸟

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2016	30 Sep 2015	30 Sep 2016	30 Sep 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,287	3,599	3,287	3,599
2	Profit/(loss) before tax	835	906	835	906
3	Profit/(loss) for the period	829	906	829	906
4	Profit/(loss) attributable to ordinary equity holders of the parent	829	906	829	906
5	Basic earnings/(loss) per share (Subunit)	0.88	0.96	0.88	0.96
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2149		0.2060

icy97

医保需求增推动营收
基因组学3年强化保健业务

2016年11月21日
（吉隆坡21日讯）随着大马对医疗保健需求提升，基因组学资源（MGRC，0155，创业板）相信有助推动现财年营业额增长，同时公司也放眼未来3年内强化保健业务。

大马基因资源营运总监萨莎诺丁今日指出，公司今年将专注于强化健康检测服务，并提升现金流。

他解释，该公司在2010财政年，营业额全部来自分析服务。到了2016财年，84%营业额贡献来自分析服务，14%由检验服务，及2%由病理检查服务贡献。

病理检查市场年增9%

他展望到了2019财年，营业额68%来自分析服务贡献，而检验服务和病理检查服务，将各贡献16%。

萨莎诺丁是在股东大会结束后，对记者发表谈话。

他续说，以我国人口来看，国内私人病理检查服务行业，全年营业额达10亿令吉，按年增长9%，主要由国民总收入和医疗支出增加、慢性疾病率提升，及劳动年龄人口增长推动。

最近，基因组学资源还推出Dtect 药物基因组学（PGx），可助降低人体对某些不良药物过敏的风险。

同时，该公司也增加在医疗保健和农业方面的分析服务，并提升宏基因组学（Metagenomics）的需求。

“宏基因组学将会是新增长动力。同时，我们认为分析服务、检验服务，及病理检查服务，可为公司提供增长机会。”

展望2017财年，公司将会通过Clinipath病理实验室，提升在健康检测服务方面的市占率，并会继续支持分析服务，因为是主要营业额贡献。

收据官方健康数据

萨莎诺丁透露，目前公司并没有任何投资计划，因为报数据和分析发展成为产品，并推销至大马和其他国家，已足够提升增长率。

“在该些产品有名气前，我们不会转向其他领域。”

目前，基因组学资源将在雅加达、曼谷，及香港寻求扩大市场机会，同时，也接到来自越南和缅甸的检查服务询问。

另外，萨莎诺丁透露，今年稍早，该公司已着手在国内收集有关健康数据的官方信息，以进行对健康检测市场首次研究。

“目前，并没有任何一个健康机构或其他国家，针对大马的健康测试行业做出任何研究。因此，我们相信，这将有助公司未来发展的部署。”

首季净利跌9%

截止9月杪首季，基因组学资源取得82万9000令吉净利，或每股净利0.88仙，较上财年同季的90万6000令吉，按年下扬8.5%。

营业额也下跌8.7%，从上财年同季的359万9000令吉，减少至328万7000令吉。

展望未来，公司将继续满足客户订单和开发遗传检测服务产品系列，并致力于继续努力探索和渗透入当地和地区未开发的市场。【e南洋】

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2016	31 Dec 2015	31 Dec 2016	31 Dec 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	2,046	3,194	5,333	6,793
2	Profit/(loss) before tax	-463	490	372	1,396
3	Profit/(loss) for the period	-471	489	358	1,395
4	Profit/(loss) attributable to ordinary equity holders of the parent	-471	489	358	1,395
5	Basic earnings/(loss) per share (Subunit)	-0.46	0.52	0.35	1.48
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2325		0.2060

icy97

基因组学1150万收购Mpath

財经  2017年04月27日
（吉隆坡27日讯）基因组学中心（MGRC，0155，创业板）今日与Ajmaks私人有限公司达成股权买卖协议，將向后者收购Mpath私人有限公司的4万9000股普通股和899万3500股可赎回可转换优先股（RCPS）股票，收购价为1150万令吉。

在收购完成后，Mpath公司將成为基因组学中心的独资子公司。MPath有3家独资子公司，分別是Clinipath、Medical Scan私人有限公司和Clinipath资本私人有限公司，3家公司主要是从事病理和医疗实验室研究服务，並向基因组学中心出租商业物业。

管理层表示，將以內部融资及银行贷款进行收购。

管理层也说，通过收购Clinipath並利用该公司在医疗领域所建立的分销网络和声誉，基因组学中心將能加速其提供基因遗传服务的部署。

而管理层也相信在收购计划完成后，Mpath公司將开始为公司营收捎来稳定的贡献。【东方网财经】

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR "COMPANY")PROPOSED ACQUISITION BY MGRC OF 50% EQUITY INTEREST IN MPATH SDN BHD FOR A TOTAL PURCHASE CONSIDERATION OF RM11.50 MILLION ("PROPOSED ACQUISITION")
On behalf of the Board of Directors (“Board”) of MGRC, Affin Hwang Investment Bank Berhad (“Affin Hwang IB”) wishes to announce that MGRC, had on 27 April 2017, entered into a conditional share sale agreement (“SSA”) with Ajmaks Sdn Bhd (“Ajmaks” or “Vendor”) for the proposed acquisition of 49,000 ordinary shares and 8,993,500 redeemable convertible preference shares (“RCPS”) of MPath Sdn Bhd (“MPath”) held by Ajmaks, representing 50% equity interest in MPath for a total purchase consideration of RM11.50 million (“Purchase Consideration”) (“Proposed Acquisition”). Please refer to the attachment for further details on the Proposed Acquisition. This announcement is dated 27 April 2017.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5409797

Attachments MGRC - Final Announcement.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2017	31 Mar 2016	31 Mar 2017	31 Mar 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	1,627	1,788	6,960	8,581
2	Profit/(loss) before tax	-94	229	278	1,625
3	Profit/(loss) for the period	-104	228	254	1,623
4	Profit/(loss) attributable to ordinary equity holders of the parent	-104	228	254	1,623
5	Basic earnings/(loss) per share (Subunit)	-0.10	0.24	0.25	1.72
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2315		0.2060

icy97

看好病理学服务
基因组学获准买Mpath

2017年6月9日
（吉隆坡8日讯）基因组学资源（MGRC，0155，创业板）看好病理学服务有强劲的增长展望，预计该市场每年营业额达10亿令吉。

该公司今日发表文告，营运总监萨莎诺丁指出，我国病理学领域还未成熟，所以未来潜能很大。

该公司是在召开股东特别大会后发表文告。

基因组学资源今日获得股东通过该公司以总值1150万令吉增持联营公司Mpath私人有限公司股权至100%的议案。

此前，基因组学资源和Qualitas医疗集团联合持有Mpath。

Mpath旗下有三家公司分别是Clinipath（大马）私人有限公司、Medical Scan和Clinipath资本私人有限公司。

Clinipath（大马）是一家病理学和医疗实验室服务供应商，在大马半岛和东马拥有19家实验室，并提供1200项医学诊断和基因检测。

该些检测对于现代医疗保健至关重要，因为医生将使用它们诊断、治疗和检测。

萨莎诺丁还说：“我们认为，病理学领域将每年增长10%。未来料更迅速的扩增，因为还有更多医生将推荐病人进行病理学测试。”

基因组学资源预计，在整合Mpath的营业额之后，该项收购的贡献，将反映在公司截至2018年6月30日财年首季营业额。

萨莎诺丁还说：“收购Clinipath是我们转至大马交易所主板，长期计划之一。”【e南洋】

icy97

icy97 发表于 28-4-2017 05:54 AM
基因组学1150万收购Mpath

財经  2017年04月27日
（吉隆坡27日讯）基因组学中心（MGRC，0155，创业板）今日与Ajmaks私人有限公司达成股权买卖协议，將向后者收购Mpath私人有限公司的4万9000股普通股和899万3500股 ...

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	MALAYSIAN GENOMICS RESOURCE CENTRE BERHAD ("MGRC" OR "COMPANY")ACQUISITION BY MGRC OF 50% EQUITY INTEREST IN MPATH SDN BHD FOR A TOTAL PURCHASE CONSIDERATION OF RM11.50 MILLION ("ACQUISITION")
We refer to the announcements dated 27 April 2017 and 8 June 2017 in relation to the Acquisition. On behalf of the Board of Directors of MGRC, Affin Hwang Investment Bank Berhad wishes to announce that the Acquisition has been completed on 30 June 2017 in accordance with the terms and conditions of the share sale agreement. Following the completion of the Acquisition, MPath is now a wholly-owned subsidiary of MGRC. This announcement is dated 30 June 2017.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2017	30 Jun 2016	30 Jun 2017	30 Jun 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	2,912	1,851	9,872	10,432
2	Profit/(loss) before tax	390	119	668	1,744
3	Profit/(loss) for the period	335	114	589	1,737
4	Profit/(loss) attributable to ordinary equity holders of the parent	335	114	589	1,737
5	Basic earnings/(loss) per share (Subunit)	0.32	0.12	0.57	1.85
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2348		0.2060

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2017	30 Sep 2016	30 Sep 2017	30 Sep 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	6,384	3,287	6,384	3,287
2	Profit/(loss) before tax	-790	835	-790	835
3	Profit/(loss) for the period	-823	829	-823	829
4	Profit/(loss) attributable to ordinary equity holders of the parent	-823	829	-823	829
5	Basic earnings/(loss) per share (Subunit)	-0.80	0.88	-0.80	0.88
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2268		0.2348